Leap Therapeutics and BeiGene Announce Exclusive Option and License Agreement for DKN-01 and Leap…
Leap Therapeutics and BeiGene announced an exclusive option and license agreement for the clinical development and commercialization of DKN-01, Leap's anti-Dickkopf-1 (DKK1) antibody,…
Read More...
Read More...
